• Stay on Top of 340B this Summer

    We are looking forward to connecting with you during the 340B Coalition Summer Conference being held July 15-17 in Washington, D.C. RxStrategies is proud to be a Pinnacle Sponsor for the event. Our team will be connecting with key leaders to discuss 340B comprehensive solutions, and share ideas on how to keep your 340B program on the right… Read more »

  • Simplify 340B with Dashboard Analytics

    Our powerful analytics platform provides users with robust and insightful visibility into their 340B program. With an intuitive, cloud-based platform, an advanced reporting machine, and reliable analytics, RxStrategies’ Dashboard Analytics solution simplifies your entire 340B program. Real-time accumulator views, WAC-spend analyses, robust drill-down capabilities, and custom report creations provide our users access to the exact… Read more »

  • 340B Program Compliance. Achieve More With Intuitive Solutions.

    It was great to connect with industry leaders during the 15th Annual 340B Coalition Winter Conference! As a pharmacist, clinic director, or C-suite executive, one of your top priorities is to provide safe and cost-effective care and ensure regulatory compliance.   RxStrategies understands the complexities of the 340B program and recognizes the importance of open communication… Read more »

  • 340B Insider – December 2018

    Welcome to the December edition of RxStrategies’ 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view. Visit our website to read more.   340B INDUSTRY NEWS Read below for recent news from 340B Health. THE U.S. HOUSE PASSES BILL TO KEEP DRUG COMPANIES FROM OVERCHARGING MEDICAID The bipartisan bill, from… Read more »

  • Clinical Insights: November 7, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Lorbrena® (lorlatinib) – New Drug Approval – November 2, 2018 – The Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with… Read more »

  • Clinical Insights: August 30, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval AltrenoTM (tretinoin) – August 24, 2018 – Ortho Dermatologics, one of the largest prescription dermatology healthcare businesses in the world, announced that the U.S. Food and Drug… Read more »

  • Clinical Insights: July 19, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval SymtuzaTM (darunavir, cobicistat, emtricitabine and tenofovir alafenamide) – July 17, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration… Read more »

  • Clinical Insights: June 21, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Moxidectin – June 13, 2018 – Medicines Development for Global Health (MDGH) and the World Health Organisation Special Programme for Research and Training in Tropical Diseases… Read more »

  • Clinical Insights: June 4, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Olumiant® (baricitinib) – June 1, 2018 – Eli Lilly and Company and Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has approved the 2-mg… Read more »